A prospective study of body weight and serum leptin levels in patients treated with topiramate

Clinical Neuropharmacology

Volumn 31, Issue 4, 2008, Pages 226-230

  Theisen, Frank M ^a   Beyenburg, Stefan ^b,c   Gebhardt, Stefan ^a   Kluge, Michael ^d,e   Blum, Werner F ^e,f   Remschmidt, Helmut ^a   Elger, Christian E ^b   Hebebrand, Johannes ^g  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b UNIVERSITY OF BONN   (Germany)

^c CENTRE HOSPITALIER DE LUXEMBOURG   (Luxembourg)

^d MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

^e LILLY DEUTSCHLAND GMBH   (Germany)

^f UNIVERSITY HOSPITAL GIESSEN   (Germany)

^g UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

Body mass index; Body weight; Leptin; Percentiles; Topiramate; Weight loss

Indexed keywords

CARBAMAZEPINE; LAMOTRIGINE; LEPTIN; PHENOBARBITAL; PHENYTOIN; TOPIRAMATE; VALPROIC ACID; ANTICONVULSIVE AGENT; ANTIOBESITY AGENT; DRUG DERIVATIVE; FRUCTOSE;

ADULT; AGED; ARTICLE; BODY MASS; BODY WEIGHT; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC VALUE; DRUG EFFECT; FEMALE; FOCAL EPILEPSY; FOLLOW UP; HORMONE BLOOD LEVEL; HUMAN; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SEX DIFFERENCE; SIDE EFFECT; STATISTICAL SIGNIFICANCE; WEIGHT REDUCTION; ADIPOSE TISSUE; BLOOD; DRUG COMBINATION; EPILEPSY; MIDDLE AGED; OBESITY; PHYSIOLOGY;

ADIPOSE TISSUE; ADULT; AGED; ANTI-OBESITY AGENTS; ANTICONVULSANTS; BODY MASS INDEX; BODY WEIGHT; DRUG THERAPY, COMBINATION; EPILEPSY; FEMALE; FRUCTOSE; HUMANS; LEPTIN; MALE; MIDDLE AGED; OBESITY; PROSPECTIVE STUDIES; SEX FACTORS;

EID: 53449099067     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/WNF.0b013e318157c5ce     Document Type: Article

References (22)

1. Ben-Menachem E, Axelsen M, Johanson EH, et al. Predictors of weight loss in adults with topiramate-treated epilepsy. Obes Res 2003;11: 556-562.
2. Chengappa KN, Chalasani L, Brar JS, et al. Changes in body weight and body mass index among psychiatric patients receiving lithium, valproate, or topiramate: an open-label, nonrandomized chart review. Clin Ther 2002;24:1576-1584.
3. Privitera MD. Topiramate: a new antiepileptic drug. Ann Pharmacother 1997;31:1164-1173.
4. McElroy SL, Arnold LM, Shapira NA, et al. Topiramate in the treatment of binge eating disorder associated with obesity: a randomized, placebo-controlled trial. Am J Psychiatry 2003;160: 255-261.
5. Shapira NA, Goldsmith TD, McElroy SL. Treatment of binge-eating disorder with topiramate: a clinical case series. J Clin Psychiatry 2000;61:368-372.
6. Dursun SM, Devarajan S. Clozapine weight gain, plus topiramate weight loss. Can J Psychiatry 2000;45:198.
7. Schüler-Springorum M, Hebebrand J, Wehmeier PM, et al. Is topiramate effective for weight loss in neuroleptic-induced obesity? 2 case reports [in German]. Z Kinder Jugendpsychiatr Psychother 2002;30:51-58.
8. Levy E, Margolese HC, Chouinard G. Topiramate produced weight loss following olanzapine-induced weight gain in schizophrenia. J Clin Psychiatry 2002;63:1045.
9. Friedman JM, Halaas JL. Leptin and the regulation of body weight in mammals. Nature 1998;395: 763-770.
10. Brömel T, Blum WF, Ziegler A, et al. Serum leptin levels increase rapidly after initiation of clozapine therapy. Mol Psychiatry 1998;3:76-80.
11. Pylv̈anen V, Knip M, Pakarinen A, et al. Serum insulin and leptin levels in valproate-associated obesity. Epilepsia 2002;43:514-517.
12. Verrotti A, Basciani F, Morresi S, et al. Serum leptin changes in epileptic patients who gain weight after therapy with valproic acid. Neurology 1999; 53:230-232.
13. York DA, Singer L, Thomas S, et al. Effect of topiramate on body weight and body composition of osborne-mendel rats fed a high-fat diet: alterations in hormones, neuropeptide, and uncoupling-protein mRNAs. Nutrition 2000;16:967-975.
14. Richard D, Picard F, Lemieux C, et al. The effects of topiramate and sex hormones on energy balance of male and female rats. Int J Obes Relat Metab Disord 2002;26:344-353.
15. Husum H, Van Kammen D, Termeer E, et al. Topiramate normalizes hippocampal NPY-LI in flinders sensitive line 'depressed' rats and upregulates NPY, galanin, and CRH-LI in the hypothalamus: implications for mood-stabilizing and weight loss-inducing effects. Neuropsychopharmacology 2003;28:1292-1299.
16. Blum WF, Juul A. Reference ranges of serum leptin levels according to body mass index, gender and developmental stage. In: Blum WF, Kiess W, Rascher W, eds. Leptin: The Voice of the Adipose Tissue Heidelberg, Leipzig: Barth; 1997: 318-326.
17. Blum WF, Englaro P, Hanitsch S, et al. Plasma leptin levels in healthy children and adolescents: dependence on body mass index, body fat mass, gender, pubertal stage, and testosterone. J Clin Endocrinol Metab 1997;82:2904-2910.
18. Lalonde J, Samson P, Poulin S, et al. Additive effects of leptin and topiramate in reducing fat deposition in lean and obese ob/ob mice. Physiol Behav 2004; 80:415-420.
19. Reife R, Pledger G, Wu SC. Topiramate as add-on therapy: pooled analysis of randomized controlled trials in adults. Epilepsia 2000;41:S66-S71.
20. Palamara KL, Mogul HR, Peterson SJ, et al. Obesity: new perspectives and pharmacotherapies. Cardiol Rev 2006;14:238-258.
21. Stanley BG, Ha LH, Spears LC, et al. Lateral hypothalamic injections of glutamate, kainic acid, d,l-alpha-amino-3-hydroxy-5-methyl-isoxazole propionic acid or N-methyl-d-aspartic acid rapidly elicit intense transient eating in rats. Brain Res 1993;613:88-95.
22. Rosenow F, Knake S, Hebebrand J. Topiramate and anorexia nervosa. Am J Psychiatry 2002;159: 2112-2113.